At a time of rapid advancements in cancer biology and innovation, researchers are facing mounting challenges in finding enough patients to recruit for clinical trials. Although this has been difficult for many years, current trends in oncology drug development may be making the problem more acute. The proliferation of targeted investigational drugs has both narrowed the pool of eligible patients …

It’s called ‘Right to Try,’ and the idea is to give access to untested and unapproved drugs to people with terminal diseases.  The bill was signed on Wednesday by President Trump, but internationally recognized cancer researcher Dr. Anthony Tolcher, the founder and CEO of San Antonio’s Next Oncology, says its a bad idea and the wrong way to go about …